期刊
DRUG DISCOVERY TODAY
卷 26, 期 11, 页码 2502-2507出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.06.011
关键词
Nanomedicines; New therapeutic entities; mRNA vaccines; Nanocarriers; BBB crossing; Protein corona; Toxicity; Regulatory framework; FDA; EMA
There is a growing interest in using nanomaterials as drug carriers for diseases such as cancers and CNS disorders. However, the regulatory framework for their human use remains limited. Characterizing the biodistribution of nanomedicines and potential toxicity from their interaction with the CNS is urgently needed.
There is growing interest in using nanomaterials as carriers for the delivery of drugs in diseases such as cancers and central nervous system (CNS) disorders. Although several nanomaterial-based products have been approved, the regulatory framework for their use in humans remains limited. Nanomedicines (NMs) are usually not designed to cross the blood-brain barrier (BBB). Given the lack of a comprehensive set of standardized methods to assess their in vivo fate, there is an urgent need to characterize NM biodistribution as well as the toxicity that could result from their interaction with the CNS. Here, we discuss the risks of potential unwanted BBB crossing and brain toxicity of nanocarriers (NCs), along with the safety assessment and current regulatory challenges related to NMs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据